Tirzepatide
Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist
Next-generation dual agonist — superior weight loss results by targeting both GIP and GLP-1 receptors.
Molecular structure image coming soon
FDA-approved prescription medication only. Same thyroid C-cell tumor precaution as semaglutide. Requires licensed prescriber.
Overview
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist approved by the FDA as Mounjaro (diabetes) and Zepbound (weight management). It demonstrates superior weight loss compared to semaglutide in head-to-head studies, with up to 22.5% body weight reduction in the SURMOUNT-1 trial. Available through compounding pharmacies during FDA drug shortages.
Mechanism of Action
Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors simultaneously. GIP receptor activation enhances insulin sensitivity, reduces glucagon, and may modulate fat cell metabolism differently than GLP-1 alone. The dual mechanism provides additive and potentially synergistic weight loss effects.
Use Cases
- ✓Chronic weight management (FDA-approved, Zepbound)
- ✓Type 2 diabetes (FDA-approved, Mounjaro)
- ✓Cardiovascular risk reduction (emerging data)
- ✓Sleep apnea (emerging)
- ✓Heart failure with preserved ejection fraction (emerging)
Research Summary
SURMOUNT-1 trial: 22.5% mean weight reduction at maximum dose vs. 2.4% placebo. SURPASS-2 showed superior A1c reduction vs semaglutide 1 mg. SURMOUNT-OSA showed 63% resolution of sleep apnea symptoms. Currently the most efficacious weight loss medication available.
Typical Dosing
2.5 mg/week titrating to 15 mg/week over 20+ weeks. Compounded versions vary by prescriber.
Administration
Prescription Only
FDA-approved prescription medication only. Same thyroid C-cell tumor precaution as semaglutide. Requires licensed prescriber.
